NAT2 preemptive pharmacogenomic guided therapy could be a potential tool for monitoring and risk stratification of ADRs such as AT-DILI in TB patients, exemplified by the relatively higher proportion of AT-DILI among the NAT2 slow acetylators in our study. Here, NAT2 is linked to tuberculosis.